Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -3.5 Million AUD | -1.73% |
| 2023 | -3.44 Million AUD | -82.93% |
| 2022 | -2.73 Million AUD | 13.19% |
| 2021 | -3.14 Million AUD | 10.65% |
| 2020 | -3.52 Million AUD | -27.5% |
| 2019 | -1.68 Million AUD | 14.25% |
| 2018 | -1.59 Million AUD | 32.48% |
| 2017 | -3.1 Million AUD | -3.38% |
| 2016 | -3.06 Million AUD | -4.23% |
| 2015 | -2.75 Million AUD | 9.06% |
| 2014 | -4.86 Million AUD | 1.6% |
| 2013 | -4.94 Million AUD | -60.46% |
| 2012 | -3.08 Million AUD | -28.08% |
| 2011 | -2.4 Million AUD | -27.2% |
| 2010 | -1.89 Million AUD | -5.57% |
| 2009 | -1.79 Million AUD | 23.67% |
| 2008 | -2.34 Million AUD | 29.66% |
| 2007 | -3.33 Million AUD | -10.89% |
| 2006 | -2.21 Million AUD | -20.43% |
| 2005 | -2.49 Million AUD | 24.92% |
| 2004 | -3.32 Million AUD | -36.34% |
| 2003 | -2.44 Million AUD | -46.06% |
| 2002 | -1.81 Million AUD | -9.43% |
| 2001 | -1.52 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -1.06 Million AUD | -57.47% |
| 2024 Q4 | -1.06 Million AUD | -0.33% |
| 2024 FY | - AUD | -2.31% |
| 2024 Q1 | -675.14 Thousand AUD | 51.54% |
| 2024 Q2 | -2.94 Million AUD | 0.0% |
| 2023 FY | - AUD | -82.93% |
| 2023 Q2 | -2.14 Million AUD | -439.66% |
| 2023 Q1 | -397.86 Thousand AUD | 51.41% |
| 2023 Q3 | -1.39 Million AUD | 35.26% |
| 2023 Q4 | -2.76 Million AUD | -99.2% |
| 2022 Q4 | -818.81 Thousand AUD | -97.29% |
| 2022 Q3 | -415.03 Thousand AUD | 77.84% |
| 2022 FY | - AUD | 13.19% |
| 2022 Q1 | -957.52 Thousand AUD | 56.2% |
| 2022 Q2 | -1.87 Million AUD | -95.56% |
| 2021 Q3 | -393 Thousand AUD | 83.66% |
| 2021 Q1 | -1.19 Million AUD | 48.38% |
| 2021 Q4 | -2.18 Million AUD | -456.3% |
| 2021 FY | - AUD | 10.65% |
| 2021 Q2 | -2.4 Million AUD | -101.89% |
| 2020 Q2 | -2.04 Million AUD | -96.58% |
| 2020 Q4 | -2.3 Million AUD | -203.13% |
| 2020 FY | - AUD | -27.5% |
| 2020 Q1 | -1.04 Million AUD | 26.42% |
| 2020 Q3 | -761.39 Thousand AUD | 62.85% |
| 2019 FY | - AUD | 14.25% |
| 2019 Q4 | -1.41 Million AUD | -100.0% |
| 2019 Q3 | -708.42 Thousand AUD | -421.61% |
| 2019 Q2 | -135.81 Thousand AUD | 0.0% |
| 2019 Q1 | -135.81 Thousand AUD | 81.07% |
| 2018 Q1 | -81.84 Thousand AUD | 84.95% |
| 2018 FY | - AUD | 32.48% |
| 2018 Q4 | -717.45 Thousand AUD | 0.0% |
| 2018 Q3 | -717.45 Thousand AUD | -776.65% |
| 2018 Q2 | -81.84 Thousand AUD | 0.0% |
| 2017 FY | - AUD | -3.38% |
| 2017 Q4 | -543.86 Thousand AUD | 0.0% |
| 2017 Q3 | -543.86 Thousand AUD | 46.21% |
| 2017 Q1 | -1.01 Million AUD | -685.65% |
| 2017 Q2 | -1.01 Million AUD | 0.0% |
| 2016 Q4 | -128.69 Thousand AUD | 0.0% |
| 2016 Q2 | -1.4 Million AUD | 0.0% |
| 2016 Q1 | -1.4 Million AUD | -401.11% |
| 2016 FY | - AUD | -4.23% |
| 2016 Q3 | -128.69 Thousand AUD | 90.83% |
| 2015 Q4 | -280.16 Thousand AUD | 0.0% |
| 2015 Q3 | -280.16 Thousand AUD | 74.46% |
| 2015 FY | - AUD | 9.06% |
| 2015 Q2 | -1.09 Million AUD | 0.0% |
| 2015 Q1 | -1.09 Million AUD | -344.79% |
| 2014 FY | - AUD | 1.6% |
| 2014 Q3 | -246.59 Thousand AUD | 81.4% |
| 2014 Q2 | -1.32 Million AUD | -0.0% |
| 2014 Q1 | -1.32 Million AUD | -65.67% |
| 2014 Q4 | -246.59 Thousand AUD | 0.0% |
| 2013 FY | - AUD | -60.46% |
| 2013 Q3 | -800.19 Thousand AUD | 0.0% |
| 2013 Q4 | -800.19 Thousand AUD | 0.0% |
| 2012 FY | - AUD | -28.08% |
| 2011 FY | - AUD | -27.2% |
| 2010 FY | - AUD | -5.57% |
| 2009 FY | - AUD | 23.67% |
| 2008 FY | - AUD | 29.66% |
| 2007 FY | - AUD | -10.89% |
| 2006 FY | - AUD | -20.43% |
| 2005 FY | - AUD | 24.92% |
| 2004 FY | - AUD | -36.34% |
| 2003 FY | - AUD | -46.06% |
| 2002 FY | - AUD | -9.43% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -149.998% |
| CSL Limited | 4.78 Billion USD | 100.073% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.067% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 40.892% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1365.394% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 79.824% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.727% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -128.15% |
| Mesoblast Limited | -62.38 Million USD | 94.383% |
| Marizyme, Inc. | -34.28 Million USD | 89.777% |
| Genus plc | 73.7 Million USD | 104.755% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 46.994% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 1.198% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 60.049% |
| ContraFect Corporation | -64.99 Million USD | 94.608% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 22.573% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | 90.135% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -50.807% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -576.482% |
| Accustem Sciences Inc. | -3.74 Million USD | 6.458% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 92.733% |
| EV Biologics, Inc. | -1.26 Million USD | -176.569% |
| Q BioMed Inc. | -617.62 Thousand USD | -467.411% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 198.11% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -53.404% |
| Biomind Labs Inc. | -1.03 Million USD | -238.746% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 51.063% |
| Skye Bioscience, Inc. | -13.54 Million USD | 74.132% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.536% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -13917.956% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 9.779% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -32.523% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 77.917% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -454.152% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 135.481% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -135.61% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -40.07% |
| GB Sciences, Inc. | -1.41 Million USD | -146.815% |
| Alpha Cognition Inc. | -9.7 Million USD | 63.892% |
| argenx SE | -216.02 Million USD | 98.378% |
| HST Global, Inc. | -5303.00 USD | -65985.027% |
| Halberd Corporation | -74.27 Thousand USD | -4618.008% |
| Enzolytics Inc. | -2.12 Million USD | -65.148% |
| Resverlogix Corp. | -11.74 Million USD | 70.154% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -14.413% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 93.667% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 91.159% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 387.961% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -21.165% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 139.582% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 52219.111% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -133.803% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1025.048% |
| AVAX Technologies, Inc. | -6.11 Million USD | 42.668% |
| ONE Bio Corp. | 13.61 Million USD | 125.744% |
| Zenith Capital Corp. | -8.6 Million USD | 59.279% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.591% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -20016.463% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -43.247% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1890.911% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -82.439% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -70.369% |
| Agentix Corp. | -1.37 Million USD | -155.475% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | -33.536% |
| Helix BioMedix, Inc. | -1.04 Million USD | -234.937% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -100.257% |
| BioStem Technologies, Inc. | -7.55 Million USD | 53.605% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1835.241% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 950.02% |
| Cell Source, Inc. | -4.27 Million USD | 17.976% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -854.327% |
| Regen BioPharma, Inc. | 1.46 Million USD | 339.058% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -274.032% |
| NovAccess Global Inc. | -1.03 Million USD | -238.664% |
| Affymax, Inc. | -14.29 Million USD | 75.485% |
| Itoco Inc. | -1.86 Million USD | -87.507% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -823.157% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -214.022% |
| CytoDyn Inc. | -18.02 Million USD | 80.562% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4334.434% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -28557.2% |
| Qrons Inc. | -40.08 Thousand USD | -8643.517% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -621.566% |
| SYBLEU INC | -141.57 Thousand USD | -2375.429% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 764.442% |
| Rebus Holdings, Inc. | -951 Thousand USD | -268.506% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -229.986% |
| Mobile Lads Corp. | -2.24 Million USD | -56.369% |
| International Stem Cell Corporation | 202 Thousand USD | 1834.896% |
| Bioxytran, Inc. | -3.82 Million USD | 8.263% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6557.464% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -42.347% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 90.23% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -7687.753% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -27.994% |
| Neutra Corp. | -181.24 Thousand USD | -1833.543% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 82.616% |
| PureTech Health plc | -11.62 Million USD | 69.859% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 82.615% |
| IXICO plc | -707 Thousand USD | -395.684% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 54.398% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 92.751% |
| CSL Limited | 4.73 Billion USD | 100.074% |
| Cellectis S.A. | -92.63 Million USD | 96.217% |